New Clarivate CMR Factbook Highlights Increasing Cost and Complexity of Phase II Trials
Clarivate Plc has announced the release of the 2020 Centre for Medicines Research (CMR) International Pharmaceutical Clinical Factbook. The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period. The report finds the number of Phase I and II trials have shown a slight decrease between 2015 and 2019, while Phase III has seen a slight increase. The overall duration for Phase II and III trials is comparable.
The Center for Medicines Research, a wholly owned subsidiary of Clarivate, has released the report to help pharmaceutical and biotechnology companies benchmark their clinical strategy against industry standards and competitors. The annual publication provides insights on clinical study, country and site level metrics from Phase I through Phase IV.
Learn more in the full release, here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
